Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoki Nagata

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
BMC Cancer|October 16, 2015
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET studyHitoshi Soda, Hiromichi Maeda, Junichi Hasegawa, et al.
Cancer Chemotherapy and Pharmacology|October 15, 2013
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathyToru Kono, Taishi Hata, Satoshi Morita, et al.
Anticancer Research|November 24, 2005
Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancerYoshifumi Nakayama, Yuzuru Inoue, Nobuo Nagashima, et al.
Japanese Journal of Clinical Oncology|February 10, 2011
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphismsYusuke Okuyama, Shoichi Hazama, Hiroshi Nozawa, et al.
Cancer Chemotherapy and Pharmacology|March 7, 2013
Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancerAkira Tsuburaya, Naoki Nagata, Haruhiko Cho, et al.
Journal of Cancer|December 7, 2018
Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal CancerShigeyoshi Iwamoto, Hiromichi Maeda, Shoichi Hazama, et al.
Anticancer Research|May 29, 2008
Prognostic significance of the local expression of interleukin-12 in patients with advanced gastric cancerNobuo Nagashima, Yoshifumi Nakayama, Yuzuru Inoue, et al.
Cancer Chemotherapy and Pharmacology|March 14, 2009
A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinomaTakaki Yoshikawa, Akira Tsuburaya, Naoki Hirabayashi, et al.
Anticancer Research|March 14, 2007
Significance of lymphangiogenesis as assessed by immunohistochemistry for podoplanin in patients with esophageal carcinomaYoshifumi Nakayama, Kentaro Matsumoto, Masaru Nagato, et al.
The Journal of Clinical Investigation|February 4, 2010
High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in miceNobuhide Matsuoka, Takeshi Itoh, Hiroshi Watarai, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
BMC Cancer|October 16, 2015
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET studyHitoshi Soda, Hiromichi Maeda, Junichi Hasegawa, et al.
Cancer Chemotherapy and Pharmacology|October 15, 2013
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathyToru Kono, Taishi Hata, Satoshi Morita, et al.
Anticancer Research|November 24, 2005
Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancerYoshifumi Nakayama, Yuzuru Inoue, Nobuo Nagashima, et al.
Japanese Journal of Clinical Oncology|February 10, 2011
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphismsYusuke Okuyama, Shoichi Hazama, Hiroshi Nozawa, et al.
Cancer Chemotherapy and Pharmacology|March 7, 2013
Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancerAkira Tsuburaya, Naoki Nagata, Haruhiko Cho, et al.
Journal of Cancer|December 7, 2018
Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal CancerShigeyoshi Iwamoto, Hiromichi Maeda, Shoichi Hazama, et al.
Anticancer Research|May 29, 2008
Prognostic significance of the local expression of interleukin-12 in patients with advanced gastric cancerNobuo Nagashima, Yoshifumi Nakayama, Yuzuru Inoue, et al.
Cancer Chemotherapy and Pharmacology|March 14, 2009
A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinomaTakaki Yoshikawa, Akira Tsuburaya, Naoki Hirabayashi, et al.
Anticancer Research|March 14, 2007
Significance of lymphangiogenesis as assessed by immunohistochemistry for podoplanin in patients with esophageal carcinomaYoshifumi Nakayama, Kentaro Matsumoto, Masaru Nagato, et al.
The Journal of Clinical Investigation|February 4, 2010
High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in miceNobuhide Matsuoka, Takeshi Itoh, Hiroshi Watarai, et al.
Pageof 9